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a b s t r a c t
Cerebrovascular reactivity (CVR), which measures the ability of cerebral blood vessels to dilate or constrict in
response to vasoactive stimuli such as CO2 inhalation, is an important index of the brain’s vascular health. Quantiﬁcation of CVR using BOLD MRI with hypercapnia challenge has shown great promises in research and clinical
studies. However, in order for it to be used as a potential imaging biomarker in large-scale and multi-site studies, the reliability of CO2-CVR quantiﬁcation across diﬀerent MRI acquisition platforms and researchers/raters
must be examined. The goal of this report from the MarkVCID small vessel disease biomarkers consortium is to
evaluate the reliability of CO2-CVR quantiﬁcation in three studies. First, the inter-rater reliability of CO2-CVR
data processing was evaluated by having raters from 5 MarkVCID sites process the same 30 CVR datasets using a
cloud-based CVR data processing pipeline. Second, the inter-scanner reproducibility of CO2-CVR quantiﬁcation
was assessed in 10 young subjects across two scanners of diﬀerent vendors. Third, test-retest repeatability was
evaluated in 20 elderly subjects from 4 sites with a scan interval of less than 2 weeks. In all studies, the CO2
CVR measurements were performed using the ﬁxed inspiration method, where the subjects wore a nose clip and
a mouthpiece and breathed room air and 5% CO2 air contained in a Douglas bag alternatively through their
mouth. The results showed that the inter-rater CoV of CVR processing was 0.08 ± 0.08% for whole-brain CVR
values and ranged from 0.16% to 0.88% in major brain regions, with ICC of absolute agreement above 0.9959
for all brain regions. Inter-scanner CoV was found to be 6.90 ± 5.08% for whole-brain CVR values, and ranged
from 4.69% to 12.71% in major brain regions, which are comparable to intra-session CoVs obtained from the
same scanners on the same day. ICC of consistency between the two scanners was 0.8498 for whole-brain CVR
and ranged from 0.8052 to 0.9185 across major brain regions. In the test-retest evaluation, test-retest CoV across
diﬀerent days was found to be 18.29 ± 17.12% for whole-brain CVR values, and ranged from 16.58% to 19.52%
in major brain regions, with ICC of absolute agreement ranged from 0.6480 to 0.7785. These results demonstrated
good inter-rater, inter-scanner, and test-retest reliability in healthy volunteers, and suggested that CO2-CVR has
suitable instrumental properties for use as an imaging biomarker of cerebrovascular function in multi-site and
longitudinal observational studies and clinical trials.
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1. Introduction

tems. Table 1 lists demographic information of the participants in all
sites by studies. The MarkVCID Consortium harmonized the study protocol and it was approved by the institutional review board (IRB) of
each site, speciﬁcally the Johns Hopkins Medicine IRB, the University
of Kentucky IRB, the University of New Mexico IRB, the University of
Southern California IRB, and the University of Texas Health San Antonio IRB. Informed written consent was obtained from each participant.
The participants included in this study had no history of neurologic or
psychiatric diseases.

Cerebrovascular reactivity (CVR), which denotes the ability of cerebral blood vessels to dilate or constrict in response to vasoactive stimuli, is an important index of the brain’s vascular health. As a dynamic
property of the cerebral blood vessels, CVR provides vital information
of vascular reserve that is complementary to steady-state vascular parameters, such as cerebral blood ﬂow (CBF) and cerebral blood volume (CBV). CVR has been shown to be a sensitive biomarker in various brain diseases and conditions such as dementia (Cantin et al.,
2011; Silvestrini et al., 2006; Sur et al., 2020; Yezhuvath et al.,
2012), arterial stenosis (De Vis et al., 2015b; Donahue et al., 2013;
Gupta et al., 2012; Mandell et al., 2008; Mikulis et al., 2005), stroke
(Geranmayeh et al., 2015; Krainik et al., 2005), small vessel disease
(Greenberg, 2006; Marstrand et al., 2002), mild cognitive impairment
(McKetton et al., 2019; Sur et al., 2020; van der Thiel et al., 2019), multiple sclerosis (Marshall et al., 2014; Pelizzari et al., 2020), brain tumors
(Fierstra et al., 2016; Pillai and Zaca, 2011; Zaca et al., 2014), traumatic
brain injury (Chan et al., 2015; Kenney et al., 2016), substance abuse
(Han et al., 2008), and normal aging (De Vis et al., 2015a; Gauthier et al.,
2013; Lu et al., 2011). Additionally, CVR can also be used to account for
vascular contributions in blood-oxygenation-level-dependence (BOLD)
signals in functional MRI studies to obtain a more quantitative measure
of task-induced neural activities (Chen and Gauthier, 2021; Davis et al.,
1998; Hoge et al., 1999; Kannurpatti and Biswal, 2008; Liu et al., 2013a;
Liu et al., 2013b; Restom et al., 2008; Song et al., 2016; Tsvetanov et al.,
2015).
CVR is typically obtained by inducing a vasoactive challenge to
the participant while monitoring changes in hemodynamic MRI signals. Among the available vasoactive challenges including the injection
of acetazolamide, inhalation of hypercapnic gas, and breath-holding,
hypercapnia inhalation has been increasingly used in recent literature
due to its potency in causing vasodilation, rapid onset and cessation
of the eﬀect, as well as recent advances in MRI-compatible gas delivery apparatus (Lu et al., 2014; Slessarev et al., 2007; Tancredi et al.,
2014; Wise et al., 2007; Yezhuvath et al., 2009). For MRI acquisition,
although CBF and CBV techniques have been utilized to monitor hemodynamic changes upon the vasoactive challenge (Davis et al., 1998;
Donahue et al., 2014; Donahue et al., 2009; Hoge et al., 1999; Hua et al.,
2011), the BOLD sequence is by far the most widely used acquisition
technique due to its superior signal-to-noise ratio (SNR) and wide availability relative to CBF and CBV MRI techniques. Therefore, there is a
surging interest to use BOLD fMRI with hypercapnia challenge to quantify CVR in research and clinical studies. However, before its wider application in large-scale studies which are typically based on a multi-site
setting, e.g. the MarkVCID study (Lu et al., 2021), reliability of CO2-CVR
in terms of sessions, raters, and scanner vendors needs to be examined.
The goal of the present report, performed as part of the MarkVCID
cerebral small vessel disease biomarkers consortium, is to systematically address these questions in a series of three instrumental validation studies. In the ﬁrst inter-rater reliability study, we evaluated the
rater-dependence of a cloud-based CVR data processing pipeline, which
is essential for broad availability of the CO2-CVR technique. In the second inter-scanner study, we conducted a multi-vendor comparison study
to evaluate the reproducibility of CO2-CVR on two MRI platforms (on
the same day). In the third study, we conducted a test-retest repeatability study to evaluate CVR across diﬀerent days (on the same scanner).
To ensure that the test-retest repeatability results are generalizable for
multi-center trials, Study 3 was conducted at diﬀerent MarkVCID sites.

2.2. CO2-CVR acquisition
The CO2 inhalation setup and procedure followed the procedure described by the MarkVCID consortium (Lu et al., 2021). Speciﬁcally, subjects were ﬁtted with a mouthpiece and a nose-clip, and mild hypercapnia air (5% CO2, 21% oxygen, and 74% nitrogen) was administered
using a Douglas bag, with a valve to switch between room-air and hypercapnic air (Lu et al., 2014). After the initial 15s of room air breathing,
subjects breathed 50s of hypercapnic air and 70s room-air alternatively
for 3 times, followed by an additional 45s room air, for a total duration
of 420 seconds. CO2 concentration in the exhaled air was sampled at 100
Hz and the resulting CO2 trace was recorded using capnography (NM3,
Philips, Pittsburgh, PA). BOLD fMRI images were continuously acquired
during the entire 420-second period. The scan parameters were: gradient echo EPI, in-plane resolution =3.4 × 3.4 mm2 , matrix size=64 × 64,
34-36 axial slices (depending on MRI scanner model) with 3.8mm slice
thickness for whole brain coverage, repetition time (TR) = 1500ms, echo
time (TE) = 21ms, ﬂip angle (FA) = 90°, 281 volumes with 6 dummy
volumes for scanner stabilization. These parameters were chosen based
on our previous technical development studies to minimize artifact in
CVR results. Speciﬁcally, Based on recent theoretical and experimental
evidence (Ravi et al., 2016), the use of a TE of 21ms, which is shorter
than those used in fMRI (typically 30-45ms), can minimize the artiﬁcially negative CVR values in the ventricle regions. A high resolution 3D T1-weighted multi-echo magnetization-prepared rapid-acquisition-ofgradient-echo (ME-MPRAGE) was performed (1 × 1 × 1mm3 voxel size,
4 echoes, TR/TE/ΔTE/TI= 2530/1.66/1.9/1300 ms for Philips scanner and 2530/1.64/1.86/1100 or 1200 ms for Siemens scanners) for
anatomic reference (Lu et al., 2021).
2.3. CO2-CVR processing pipeline
CVR data processing was performed using a cloud-based online processing tool referred to as CVR-MRICloud (Version 5,
https://braingps.mricloud.org/cvr.v5) (Baker et al., 2019). With this
cloud-based processing tool, the users uploaded the de-identiﬁed CVR
data ﬁles to the cloud server, including the BOLD image ﬁles, the CO2
trace ﬁle (after manually trimmed to remove extra recording periods
before the mouthpiece was put on and after it was taken oﬀ), and
the T1-MPRAGE image (average of the ME-MPRAGE images across all
echoes) which allow the normalization of CVR results to the standard
MNI space. Next, the server performed the CVR processing automatically. Once completed, the users downloaded a set of output results
from the server, including the CVR maps and CVR values of the whole
brain and diﬀerent anatomic brain regions.
The CVR processing performed on the cloud server followed the
method established previously (Liu et al., 2019; Lu et al., 2014;
Yezhuvath et al., 2009). Brieﬂy, the BOLD data were ﬁrst motion corrected and smoothed by an 8mm Gaussian kernel. The end-tidal CO2
(EtCO2) curve was extracted from the CO2 trace using an automatic
algorithm to identify the peak CO2 of each breath. The EtCO2 curve
was time-shifted to align with the whole-brain BOLD signal time course
and then used as a regressor for a voxel-wise linear regression with the
BOLD data, which yields the CVR map. The CVR map was then coregistered to the MPRAGE-image-space and transformed to the MNI-space

2. Methods
2.1. General
Five MarkVCID sites, all located in the United States, participated
in this study. All sites were equipped with 3T whole-body MRI sys2
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Table 1
Scanner and demographic information of the study.
Site 1
Inter-rater reliability
Scanner
Philips Achieva
N
15
M/F
7M/8F
Age
69.5±4.9
Inter-scanner reproducibility
Scanner
Philips Achieva and Siemens Prisma
N
10
M/F
7/3
23.9±2.4
Age (y)
Test-retest repeatability
Scanner
Philips Achieva
N
6
M/F
0M/6F
Age (y)
64.3±5.6

Site 2

Site 3

Site 4

Site 5

Siemens Trio
6
2M/4F
72.4±5.7

Siemens Prisma
7
2M/5F
68.8±3.6

Siemens Trio
2
0M/2F
78.4±3.6

–
–
–
–

–
–
–
–

–
–
–
–

–
–
–
–

–
–
–
–

Siemens Trio
4
1M/3F
78.9±2.9

Siemens Prisma
4
1M/3F
75.0±5.1

–
–
–
–

Siemens Trio
6
1M/5F
67.9±3.9

using SPM. Finally, the segmented MPRAGE image was used to calculate ROI CVR values by applying the anatomical ROI masks to the BOLD
data to obtain ROI-time-courses for ROI CVR computation. The ﬁnal
CVR value is written in the units of % BOLD signal change per mmHg
of EtCO2 (%/mmHg). Brain regions investigated included gray matter
ROIs of frontal lobe, parietal lobe, temporal lobe, limbic lobe, occipital lobe, insular, basal ganglia and thalamus (Wu et al., 2016), cerebral
white matter ROI, as well as calculation of a whole-brain CVR value that
includes both gray and white matters.

2.6. Test-retest repeatability (Study 3)
Test-retest repeatability indicates the degree of agreement of CVR
measurements on the same scanner but on diﬀerent days. To evaluate
the test–retest repeatability of CO2-CVR on diﬀerent days, four participating sites (Sites 1, 2, 3, and 5) recruited a total of 20 individuals.
Each participant received two CO2-CVR scans using the same scanner
and protocol with a gap 4 to 13 days (average 8.9±2.9 days). The number of the subjects from each site are shown in Table 1. This study
was performed in a multi-site fashion to simulate conditions in a multicenter trial where sites will have varying levels of prior experience with
CVR-speciﬁc procedures (e.g., placement of mouthpiece and switching
of gas). The participants in this test-retest study are also representative
in age of individuals expected to be enrolled in a future small vessel disease trial. (Table 1). On-site training of the CVR experiment procedure
was given at each participating site by the lead site prior to the start
of the study. Participating sites shared the de-identiﬁed data with the
lead site for analysis. One subject from Site 2 was excluded due to the
absence of CO2 inhalation in the ﬁrst scan, and another subject from
Site 3 was excluded due to mouthpiece displacement (resulting in CO2
trace recording failure) during the second scan, so these two subjects
were excluded from the test-retest analysis, resulting in 18 subjects x 2
repetitions CVR measures across 4 sites. Basal and ΔEtCO2 diﬀerences
between the tests were also accounted for (Hou et al., 2020).

2.4. Inter-rater reliability (Study 1)
The inter-rater reliability indicates the degree of agreement among
independent raters assessing the same dataset. The objective of this analysis was to investigate whether diﬀerent raters reported consistent CVR
results obtained in the same sample. This sample included 30 participants imaged with the above-described CO2-CVR protocol at four different sites (Sites 1, 2, 3, and 4). The 30 CO2-CVR datasets were sent to
all ﬁve participating sites (Sites 1, 2, 3, 4, and 5) for analysis. Written instructions and a webinar were given to the investigators from
each participating site for training (Training materials are published
at https://markvcid.partners.org/consortium-protocols-resources). One
rater from each site analyzed the datasets independently using the CVRMRICloud processing pipeline and shared outputs with the lead site (site
1), resulting in 5 raters × 30 subjects CVR measures.

2.7. Statistical analyses
All statistical analyses were performed using Matlab and visualized using Excel. Regression analysis and Bland-Altman (Bland and Altman, 1986) plot were used to visualize the agreement of whole-brain
CVR values obtained from diﬀerent sites (inter-rater reliability study),
scanners (inter-scanner reproducibility study) and sessions (test-retest
repeatability study). Variability was assessed by coeﬃcient of variance (CoV), given by standard deviation across measures divided by
mean values. Intraclass correlation coeﬃcient (Shrout and Fleiss, 1979)
(ICC) were used to evaluate the whole-brain CVR and ROI CVR values. Speciﬁcally, ICC using a 2-way (same raters) random-eﬀects model
(same participants) with single measure and absolute agreement form
(noted as ICCAA ) was calculated for CVR values obtained from diﬀerent
sites (inter-rater reliability study) and sessions (test-retest repeatability
study). ICC using a 2-way random-eﬀects model with single measure
and consistency form (noted as ICCC ) was calculated for CVR values
obtained from diﬀerent scanners (inter-scanner reproducibility study)
considering systematic error between them. In the inter-scanner reproducibility study, two measures from each scanner were averaged to reduce physiological variation in the inter-scanner comparison, and additional single-site inter-session reliability evaluation was performed for
each scanner by calculating inter-session CoV and ICCAA using the two

2.5. Inter-scanner reproducibility (Study 2)
The inter-scanner reproducibility indicates the ability to obtain similar observations using the same methodology on diﬀerent scanners. To
evaluate the reproducibility of CO2-CVR on diﬀerent MRI platforms,
a cross-vendor comparison was performed at the lead site (Site 1).
Ten healthy subjects (3 females, age 23.9±2.4y) participated in this
study. Each subject was scanned on a Philips (Achieva) and a Siemens
(Prisma) 3 T scanner within a 2.5-hour period. On each scanner, CVR
scans were performed twice with repositioning. The order of the scanners was counterbalanced across subjects. The imaging acquisition and
analysis protocol followed that described earlier, resulting in 2 vendors x 10 subjects x 2 repetitions CVR measures. To reduce the effects of physiological variations (Bright et al., 2011; Hou et al., 2020),
the CVR values were further corrected for basal and ΔEtCO2 diﬀerences between repetitions and across the scanners using the association between them established previously (Hou et al., 2020), given
by CVR2, corr = CVR2 + 0.0036(EtCO2basal,2 - EtCO2basal,1 ) + 0.0072
(ΔEtCO22 - ΔEtCO21 ).
3
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Figure 1. Comparisons of whole-brain CVR obtained from ﬁve diﬀerent sites in the inter-rater reliability study (Study 1). Scatterplots are shown in the upper triangle
panel with linear regression line in black and identity line as dashed gray line. Bland-Altman plots are shown in the lower triangle panel with black lines indicate
mean and dashed lines indicates 95% conﬁdence interval. Each blue dot represents one subject.

whole-brain CVR measures obtained from each scanner. ICC values less
than 0.5, between 0.5 and 0.75, between 0.75 and 0.9, and more than
0.90 were considered to be poor, moderate, good, and excellent, respectively (Koo and Li, 2016). For the inter-scanner reproducibility study
and the test-retest repeatability study, paired t-test was also used to compare the repeated measures. A p<0.05 was considered to be signiﬁcantly
diﬀerent.

pipeline on the same CO2-CVR datasets. ICCAA of regional CVR values
generated by the ﬁve sites ranged from 0.9959 to 0.9999 (see Table 2).
3.2. Inter-scanner reproducibility
Figure 2a showed the CVR maps obtained from a representative subject at each session of each scanner. Visual inspection suggested good
agreement between the scanners. Scatter plot and Bland-Altman plot of
whole-brain CVR for 10 individuals imaged at two diﬀerent scanners
are shown in Figure 2b and 2c, respectively. Mean whole-brain CVR of
the 10 healthy young subjects was 0.133±0.029 %ΔBOLD/mmHg and
0.126±0.025 % ΔBOLD/mmHg from the Philips scanner and Siemen
scanner, respectively, with no signiﬁcant diﬀerence between them
(p=0.16). Inter-scanner CoV was 6.90 ± 5.08% for whole-brain CVR
values, and ranged from 4.69 % to 12.71 % in major brain regions (see
Table 2). ICCC of whole-brain CVR measures from the two scanners was
found to be 0.8498, p=0.0005. ICCC of regional CVR values between
two scanners ranged from 0.8052 to 0.9185 (see Table 2), indicating
good to excellent reproducibility.
Mean basal EtCO2 of the 10 subjects was 38.42±3.57 mmHg and
39.15±3.57 mmHg from the Philips scanner and Siemens scanner,

3. Results
3.1. Inter-rater reliability
Figure 1 illustrates the whole-brain CVR values of 30 individuals
processed by independent raters of the ﬁve participating sites. Visual
inspection suggested good agreement across the sites. Inter-rater CoV
was 0.08 ± 0.08% for whole-brain CVR values, and ranged from 0.16 %
to 0.88 % in major brain regions (see Table 2). ICCAA of whole-brain CVR
measures generated by the ﬁve sites was found to be 0.9999, p<0.0001,
indicating excellent reliability, i.e. a very strong agreement, between
the diﬀerent raters (i.e. sites) when using the CVR-MRICloud analysis
4
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Table 2
Summary of the inter-rater, inter-scanner and inter-session reproducibility of the study.
Whole-brain
Inter-rater reliability
CoV (%)
0.08±0.08
0.9999
ICCAA
Inter-scanner reproducibility
CoV (%)
6.90±5.08
0.8498
ICCC
Test-retest repeatability
CoV (%)
17.09±16.28
0.6568
ICCAA

Frontal

Parietal

Temporal

Limbic

Occipital

Insula

BasalGang

Thalamus

White matter

0.34±0.95
0.9977

0.50±1.56
09976

0.49±1.03
0.9995

0.33±0.35
0.9970

0.88±0.92
0.9999

0.21±0.21
0.9999

0.22±0.37
0.9999

0.16±0.11
0.9997

0.41±1.17
0.9972

7.99±5.93
0.9185

8.21±6.61
0.8528

7.53±5.56
0.8052

8.46±7.87
0.8872

7.92±6.96
0.8068

12.71±13.32
0.8364

10.27±9.56
0.9175

4.69±4.39
0.8687

12.04±8.01
0.6592

15.92±13.29
0.7658

18.14±10.89
0.7427

16.66±14.60
0.7097

17.82±16.05
0.7281

19.95±12.23
0.6375

16.98±17.17
0.7542

17.45±19.20
0.7729

18.58±16.59
0.7139

22.65±20.45
0.4506

Figure 2. Comparisons of whole-brain CVR obtained from two scanners in the inter-scanner reproducibility study (Study 2). (a) CVR maps of a representative subject
at diﬀerent sessions of diﬀerent scanners. (b) Scatterplot of the whole-brain CVR measures with linear regression line in black and identity line as dashed gray line.
(c) Bland-Altman plot of the whole-brain CVR measures with black lines indicate mean and dashed lines indicates 95% conﬁdence interval. Each dot represents data
from one subject.

respectively. Mean EtCO2 change (ΔEtCO2) in response to the 5%
CO2 inhalation was 9.59±1.68 mmHg and 9.47±1.26 mmHg, respectively. Mean whole-brain BOLD percent signal change (%ΔBOLD) due
to CO2 inhalation was 1.31±0.37% and 1.23±0.25%, respectively. No
signiﬁcant inter-scanner diﬀerences were found for these parameters
(p>0.24). Inter-scanner CoV and ICCC of these measures from the two
scanners are shown in Table 3.

Additionally, same-day inter-session (with repositioning) analysis in
the 10 subjects showed that for whole-brain CVR measures, inter-session
CoV was 6.30±8.97% for the Philips scanner, and 7.39±7.03% for the
Siemens scanner, with no signiﬁcant diﬀerence between them (p=0.86).
Inter-session ICCAA was 0.8744, p<0.0001 for the Philips scanner, and
0.7781, p=0.001 for the Siemens scanner. For the Philips sessions, same
day inter-session CoV was 1.59±1.51%, 5.95±6.44% and 9.58±6.14%

5
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Table 3
Summary of the basal EtCO2, ΔEtCO2 and ΔBOLD results in the interscanner and inter-session reproducibility studies.
Basal EtCO2 (mmHg)
Inter-scanner reproducibility
CoV (%)
3.00±2.13
0.8670
ICCC
Test-retest repeatability
CoV (%)
18.29±17.12
0.6498
ICCAA

ΔEtCO2 (mmHg)

%ΔBOLD (%)

6.47±3.74
0.7215

11.43±8.82
0.6886

18.79±11.39
0.7152

18.51±17.30
0.7429

the selection of the segment of the CO2 trace to be used. Slight variations in this “CO2 trimming” step, such as how much extra recording to
be included before the ﬁrst CO2 inhalation period and after the last CO2
inhalation period decided by each rater, could aﬀect the determination
of the optimal time-shift between EtCO2 and BOLD signal time courses,
which in turn inﬂuences the CVR value. However, our results suggested
that this rater-dependence has minimal eﬀects in CVR quantiﬁcation.
There has been no study in literature that examined the inter-rater reliability of CO2-CVR quantiﬁcation previously, so our study provided the
ﬁrst reference for the reliability of CO2-CVR quantiﬁcations using the
CVR-MRICloud tool (Baker et al., 2019).

for basal EtCO2, ΔEtCO2 and %ΔBOLD, respectively, with ICCAA of
0.9127, 0.7845 and 0.9359, respectively. For the Siemens sessions, same
day inter-session CoV was 2.63±2.54%, 6.38±4.28% and 14.34±11.56%
for basal EtCO2, ΔEtCO2 and %ΔBOLD, respectively, with ICCAA of
0.7571, 0.7890 and 0.5840, respectively. No signiﬁcant diﬀerences between the ICC values of the two scanners were found for any of these
parameters (p>0.19).

4.2. Inter-scanner reproducibility
Inter-scanner reliability was evaluated by comparing quantitative
CVR values obtained from a group of young individuals scanned on
two diﬀerent MRI scanners on the same day. Standardization of MRI
protocols across vendors is the ﬁrst step in virtually all MRI techniques
for large-scale, multi-site studies (Jack et al., 2008). Due to the diﬀerences in hardware speciﬁcations and software programming environments across scanners, it is not possible to match every parameter between the BOLD MRI protocols of the two vendors. For the BOLD MRI
sequence, the most important components are TR, TE and FA. We used
the harmonized CVR protocols of the MarkVCID study (Lu et al., 2021),
where TR/TE/FA are identical across vendors and the other parameters
are also maximally consistent. Whole-brain CVR measures were found
to be highly consistent between the Philips and Siemens systems, with
ICCC of 0.85 and CoV of 6.9%, which is comparable to the same-day
within scanner, inter-session ICCAA and CoV obtained from the same
subjects. This inter-scanner CoV of 6.9% for BOLD CVR is slightly higher
than the anatomic measures, such as brain volume (around 4% for
whole brain measures (Huppertz et al., 2010)) and ADC (around 5%
(Magnotta et al., 2012)), but is lower than other functional measures,
such as ASL (about 15% (Mutsaerts et al., 2015)) and functional MRI
(about 20% (Friedman et al., 2006)). If using ASL CoV as reference,
both whole-brain and regional CVR showed excellent inter-scanner reproducibility. To our knowledge, this is the ﬁrst report of inter-scanner
variability of CVR quantiﬁcation. These results support the validity to
pool data from multiple sites when using the MarkVCID CVR protocol
(Lu et al., 2021) without increasing the heterogeneity of the imaging
measurements.

3.3. Test-retest repeatability
Figure 3 illustrates test and retest whole-brain CVR measures in 18
subjects across 4 sites. Mean whole-brain CVR of the 18 elderly subjects
was 0.109±0.037 %ΔBOLD/mmHg and 0.111±0.040 % ΔBOLD/mmHg
from the test-retest scans, respectively, with no signiﬁcant diﬀerence
between them (p=0.90). Test-retest CoV was 17.09 ± 16.28% for wholebrain CVR values, and ranged from 15.92% to 22.65% in major brain
regions (see Table 2). ICCAA between test and retest whole-brain CVR
measures was found to be 0.6568, p=0.0014. ICCAA of regional CVR
values between the two measures ranged from 0.4506 to 0.7729 (see
Table 2), indicating moderate to good repeatability in whole-brain and
gray matter regions. There was not a site eﬀect in the CoV values for the
four sites.
Mean basal EtCO2 of the 18 subjects was 38.91±8.08 mmHg
and 40.82±5.59 mmHg from the test-retest scans, respectively. Mean
ΔEtCO2 was 8.72±2.64 mmHg and 8.79±2.67 mmHg, respectively.
Mean %ΔBOLD was 0.80±0.36% and 0.91±0.39%, respectively.
No signiﬁcant test-retest diﬀerences were found for these parameters (p>0.24). Test-retest CoV was 7.12±17.0%, 16.37±15.80% and
32.14±241.85% for basal EtCO2, ΔEtCO2 and %ΔBOLD, respectively,
with ICCAA of 0.4666, 0.5392 and 0.4919, respectively.

4.3. Test-retest repeatability

4. Discussion

Test-retest repeatability was evaluated by comparing CVR values obtained using the same MRI scanners on diﬀerent days within an interval
of <2 weeks, an interval in which an individual’s vascular disease is unlikely to change. The evaluation of test-retest reliability of CVR measurements is critical for longitudinal studies, as it is important to interpret
longitudinal changes observed with reference to intra-subject variations
due to normal physiological variations and MRI acquisition diﬀerences
such as subject and imaging slice positioning, shimming, and operator
technique. Our results showed that test-retest CoV was about 17% of
whole brain CVR and 16-20% of regional CVR across diﬀerent sites, with
ICC of absolute agreement to be 0.66 for whole-brain CVR and 0.650.78 for regional CVR in gray matter, when measured on diﬀerent days
within a two-week interval. These CoV values were higher than those
observed in Study 2 (∼7%), which were obtained by a single-site (i.e.
the lead-author’s site) on the same day, but compared with typical fMRI
measures, they are considered good. A previous study showed a CoV of
about 11% and ICC of about 0.75 for CO2 CVR measured in 10 young
subjects at a single site 3T scanner with 2-days interval (Leung et al.,
2016). A single-site study on 19 healthy volunteers reported ICC of 0.81
and 0.66 for gray matter and white matter CVR, respectively, using a
1.5T scanner with a median range of 15 days apart (Kassner et al., 2010).

In the present work we performed a series of studies to evaluate
the variability, reliability and reproducibility of CVR quantiﬁcation using BOLD MRI with hypercapnia inhalation, which provides important benchmarks for CO2-CVR as a quantitative biomarker for the future clinical studies. We focused on instrumental validation of three
biomarker properties that would be essential to applying CVR to a large
multi-center trial: inter-rater reliability, inter-scanner reproducibility,
and test-retest repeatability.
4.1. Inter-rater reliability
Inter-rater reliability was evaluated by comparing the quantitative
CVR values obtained by raters at ﬁve diﬀerent sites analyzing the same
CO2-CVR data. With written instructions and a training webinar, all sites
were able to process the CO2-CVR data independently using the CVRMRICloud analysis pipeline. Our results showed that ICC of absolute
agreement of CVR values across all participating sites was above 0.997
for whole-brain and major brain regions, reﬂecting excellent inter-rater
reliability in CO2-CVR quantiﬁcation. The variability in the CVR results
originates from a manual step in the processing pipeline, which involves
6
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Figure 3. Comparisons of whole-brain CVR obtained from diﬀerent days in the test-retest repeatability study (Study 3). (a) CVR maps of one representative subject
from each site at diﬀerent days. (b) Scatterplot of the whole-brain CVR measures with linear regression line in black and identity line as dashed gray line. (c)
Bland-Altman plot of the whole-brain CVR measures with black lines indicate mean and dashed lines indicates 95% conﬁdence interval. Each dot represents data
from one subject. Data from diﬀerent sites are shown in diﬀerent colors.

Another single-site study on 15 healthy subjects reported CoV of 11.7–
70.2% for gray matter CVR and 27.5–141.0% for white matter CVR in
various brain regions using similar hypercapnia inhalation paradigm on
a 1.5T scanner in two separate visits (Thrippleton et al., 2018).
The higher CoV observed in Study 3 relative to the inter-scanner
variability shown in Study 2 may be attributed to several causes. Differences could reﬂect actual day-to-day variability over the interscan
interval of up to 2 weeks. The correction of basal and ΔEtCO2 helped
to reduce the day-to-day variation of EtCO2, as without this correction,
CoV and ICCAA of the whole-brain CVR in Study 3 was 18.66±17.33%
and 0.4859, respectively. However, there are other sources that contribute to the day-to-day variability. In particular, we did not control
the participants’ uptake of vasoactive drugs or beverages prior to the
MRI scan. For example, it is known that caﬀeine can reduce CBF by up
to 25% (Xu et al., 2015), thus consumption of coﬀee may alter the measured CVR value. Second, older subjects may reveal a higher inter-scan
CoV due to a higher tendency to move or otherwise not comply with
instructions (e.g. opening their mouths) as well as potentially greater
underlying day-to-day variations in brain physiology. Finally, CO2-CVR

testing requires the delivery of CO2 gas mixture inside the MRI scanner as well as recording of end-tidal CO2 trace. Thus, the skill level of
the experimenter may play a role in the quality of the data (e.g. when
the mouthpiece is not placed comfortably, the subject may have greater
motion). This can aﬀect the success rate and lead to data exclusion due
to technical issues related to CO2 delivery and recording. It should also
be mentioned that the CoV of CVR is much smaller than the CoV of
%ΔBOLD in both the inter-scanner and test-retest studies. This is because the variations in BOLD signal changes are largely attributed to
EtCO2 variations, especially ΔEtCO2 variations. Therefore, the calculated CVR values, which accounted for EtCO2 variations, have smaller
CoV than %ΔBOLD alone.
Nonetheless, the observed CoV of approximately 17% is within the
range of previous studies, and is less variable than typical task-fMRI
measures (Clement and Belleville, 2009; Gountouna et al., 2010). Importantly, it should be emphasized that disease-related diﬀerences in
CVR are often greater than 50% (Cantin et al., 2011; Sur et al., 2020;
Yezhuvath et al., 2012). Thus, CVR still possesses the sensitivity in detecting pathological eﬀects in brain diseases. Assuming a 15% diﬀerence
7
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in whole-brain CVR between cognitive impaired patients and healthy
controls (Sur et al., 2020), with the CoV of 17%, 20 subjects are needed
for each group to detect a signiﬁcant group diﬀerence with a power
of 0.8. Similarly, assuming a 25% diﬀerence in CVR between multiple
sclerosis patients and healthy controls (Marshall et al., 2016), 8 subjects are needed for each group to detect a signiﬁcant group diﬀerence
with a power of 0.8. In future clinical trials, test-retest variability can
be further reduced by improvements in experimental procedures such
as control of uptake of vasoactive drugs and/or beverages prior to the
MRI scan as well as enhanced training of personnel performing the CVR
MRI measurement.
There are a few limitations of this study. First, the sample size of
some sites in Study 3 is considered small. Therefore, no comparisons
among the individual sites were performed due to this sample size limitation. Second, we focused on the reproducibility of CVR values, but
did not study the CO2 bolus transit and response time which can also be
a sensitive index in cerebrovascular diseases, especially in large vessel
diseases. There are a few advanced CVR analysis methods that could be
evaluated, which yield transit/delay maps and even functional connectivity maps (Bhogal et al., 2015; Blockley et al., 2011; Donahue et al.,
2016; Hou et al., 2019). It should also be noted that there are two
categories of CO2 delivery for CVR mapping (Liu et al., 2019), which
are the ﬁxed CO2 concentration in the inspired gas (Lu et al., 2014;
Tancredi et al., 2014) and ﬁxed CO2 concentration in the exhaled air
(Slessarev et al., 2007; Wise et al., 2007). In this study we only evaluated the CVR mapping method using ﬁxed CO2 concentration (5%)
in the inspired gas. Compared with the ﬁxed exhaled CO2 concentration, the ﬁxed inspiration method is less expensive, involves less training and preparation for both the researcher and the participant, and
troubleshooting is simpler. Therefore, it is thought to be more suited for
multi-site studies where researchers are not always experienced with
CVR mapping. In the MarkVCID study, the gas delivery packages were
disseminated to all participating site by the lead site, following the item
list published previously (Lu et al., 2014). The nose clip and mouthpiece setup were able to ﬁt 32 and 64 channel head coils at all sites.
Researchers in the participating site were trained on-site by the lead
site for the procedure of the CVR experiment. With proper preparation
prior to each experiment, the setup time of nose clip and mouthpiece
for the subjects were 3-5min before the CVR scan. Out of the 40 CVR
experiments in the scan-rescan reproducibility study, only two failed
to provide usable datasets due to technical error (CO2 air was not delivered) and subject not cooperating (subject pushed mouthpiece out
during the scan), suggesting the eﬀectiveness of the training. The CVR
analysis training were conducted as an online webinar, and all sites were
able to follow the instructions and generate CVR mapping results.
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